Physician profile
David Randell
NPI 1932198611
$18,155.42
in general payments reported to CMS, 2019-2025
47 companies · $1,478 in 2025
The $1,478 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,046 · 2020: $2,734 · 2021: $4,213 · 2022: $2,564 · 2023: $2,319 · 2024: $1,802 · 2025: $1,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,599.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,956.50 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $2,239.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,705.60 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,512.14 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $1,382.34 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Biohaven Pharmaceuticals, INC. | $1,268.99 | 2021 | |
| Pfizer INC. | $1,221.32 | 2019-2025 | |
| Amgen INC. | $849.57 | 2019-2025 | Otezla, Repatha, Evenity |
| Allergan, INC. | $653.28 | 2019-2020 | |
| Amarin Pharma, INC. | $504.72 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $345.99 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $325.37 | 2019-2024 | Jardiance |
| Sumitomo Pharma America, INC. | $280.05 | 2023-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $253.30 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $251.17 | 2020-2025 | Rexulti |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Randell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.